Evidence map›Paper›PMID 26565710›Full record

ArticlePloS one2015

Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode.

Jessica Karlsson, Carmine M Morgillo, Alessandro Deplano, Giovanni Smaldone, Emilia Pedone, F Javier Luque, Mona Svensson, Ettore Novellino, Cenzo Congiu, Valentina Onnis and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Molecular Basis for Non-Covalent, Non-Competitive FAAH Inhibition.International journal of molecular sciences · 2022
    Article
  2. Article
  3. Design, synthesis andJournal of enzyme inhibition and medicinal chemistry · 2021
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Jessica KarlssonDepartment of Pharmacology and Clinical Neuroscience, Pharmacology Unit, Umeå University, Umeå, Sweden.
Carmine M MorgilloDepartment of Pharmacy, Università degli Studi di Napoli Federico II, Napoli, Italy.
Alessandro DeplanoDepartment of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, via Ospedale 72, Cagliari, I-09124, Italy.
Giovanni SmaldoneInstitute of Biostructures and Bioimaging, CNR, Naples, Italy.
Emilia PedoneInstitute of Biostructures and Bioimaging, CNR, Naples, Italy.
F Javier LuqueDepartament de Fisicoquímica and Institut de Biomedicina (IBUB), Facultat de Farmàcia, Universitat de Barcelona, Santa Coloma de Gramenet, Spain.
Mona SvenssonDepartment of Pharmacology and Clinical Neuroscience, Pharmacology Unit, Umeå University, Umeå, Sweden.
Ettore NovellinoDepartment of Pharmacy, Università degli Studi di Napoli Federico II, Napoli, Italy.
Cenzo CongiuDepartment of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, via Ospedale 72, Cagliari, I-09124, Italy.
Valentina OnnisDepartment of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, via Ospedale 72, Cagliari, I-09124, Italy.
Bruno CatalanottiDepartment of Pharmacy, Università degli Studi di Napoli Federico II, Napoli, Italy.
Christopher J FowlerDepartment of Pharmacology and Clinical Neuroscience, Pharmacology Unit, Umeå University, Umeå, Sweden.
Umeå University · SEUniversity of Cagliari · ITUniversity of Naples Federico II · ITInstitute of Biostructure and Bioimaging · ITUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCombined fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX) inhibition is a promising approach for pain-relief. The Flu-AM1 and Ibu-AM5 derivatives of flurbiprofen and ibuprofen retain similar COX-inhibitory properties and are more potent inhibitors of FAAH than the parent compounds. However, little is known as to the nature of their interaction with FAAH, or to the importance of their chirality. This has been explored here. METHODOLOGY/PRINCIPAL

findingsFAAH inhibitory activity was measured in rat brain homogenates and in lysates expressing either wild-type or FAAH(T488A)-mutated enzyme. Molecular modelling was undertaken using both docking and molecular dynamics. The (R)- and (S)-enantiomers of Flu-AM1 inhibited rat FAAH with similar potencies (IC50 values of 0.74 and 0.99 μM, respectively), whereas the (S)-enantiomer of Ibu-AM5 (IC50 0.59 μM) was more potent than the (R)-enantiomer (IC50 5.7 μM). Multiple inhibition experiments indicated that both (R)-Flu-AM1 and (S)-Ibu-AM5 inhibited FAAH in a manner mutually exclusive to carprofen. Computational studies indicated that the binding site for the Flu-AM1 and Ibu-AM5 enantiomers was located between the acyl chain binding channel and the membrane access channel, in a site overlapping the carprofen binding site, and showed a binding mode in line with that proposed for carprofen and other non-covalent ligands. The potency of (R)-Flu-AM1 was lower towards lysates expressing FAAH mutated at the proposed carprofen binding area than in lysates expressing wild-type FAAH. CONCLUSIONS/SIGNIFICANCE: The study provides kinetic and structural evidence that the enantiomers of Flu-AM1 and Ibu-AM5 bind in the substrate channel of FAAH. This information will be useful in aiding the design of novel dual-action FAAH: COX inhibitors.

Indexed as

AmidohydrolasesAminopyridinesAnimalsBrainCyclooxygenase InhibitorsDrug DesignFatty Acid Amide HydrolasesFlurbiprofenHeLa CellsHumansHydrolysisIbuprofenInhibitory Concentration 50KineticsMaleMiceAmidohydrolasesAminopyridinesCyclooxygenase InhibitorsFatty Acid Amide HydrolasesFlurbiprofenflurbiprofen 2-amino-3-methylpyridine amideIbuprofenibuprofen 2-amino-3-methylpyridine amideProstaglandin-Endoperoxide SynthasesRecombinant Proteins

Identifiers

PMID26565710
PMCPMC4643906
OpenAlexW2225281851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.